ITCI logo

Intra-Cellular Therapies Inc.

ITCI

ITCI: Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

more

Show ITCI Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of ITCI by members of U.S. Congress

Politician Type Traded
Josh Gottheimer House / D Purchase $1,001 - $15,000 Dec. 21, 2021
Roger W. Marshall House / R Purchase $1,001 - $15,000 May. 01, 2017
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by ITCI's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $40,000 Jul 17, 2023 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $80,000 Jun 21, 2023 Issue: Medicare/Medicaid
  • $50,000 Jan 19, 2023 Issue: Health Issues Medicare/Medicaid
  • $15,000 Nov 21, 2022 Issue: Medicare/Medicaid Health Issues
  • $20,000 Oct 20, 2022 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $10,000 Apr 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $20,000 Feb 28, 2005 Issue: Budget/Appropriations
  • $20,000 Aug 20, 2004 Issue: Budget/Appropriations
U.S. Patents

New patents grants

  • Patent Title: Organic compounds Aug. 15, 2023
  • Patent Title: Pharmaceutical capsule compositions comprising lumateperone mono-tosylate Jul. 04, 2023
  • Patent Title: Pharmaceutical compositions comprising 4-(6br,10as)-3-methyl-2, 3, 6b, 9, 10, 10a-hexahydro-1h, 7h-pyrido[3′, 4′, 5] pyrolo[1,2,3-de] quinoxalin-8yl)-1-(4-fluorophenyl)-butane-1-one and methods of treating conditions of the central nervous system Jun. 20, 2023
  • Patent Title: Organic compounds Jan. 24, 2023
  • Patent Title: Uses Nov. 22, 2022
  • Patent Title: Organic compounds Nov. 08, 2022
  • Patent Title: Pde1 inhibitors for ophthalmic disorders Oct. 11, 2022
  • Patent Title: Substituted heterocycle fused gamma-carbolines synthesis Sep. 27, 2022
  • Patent Title: Salts and crystals Sep. 13, 2022
  • Patent Title: Organic compounds Aug. 30, 2022
  • Patent Title: Hydrochloric acid salt of (6br,10as)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline Aug. 09, 2022
  • Patent Title: Organic compounds Jul. 05, 2022
  • Patent Title: Amorphous solid dispersions May. 17, 2022
  • Patent Title: Amorphous solid dispersions Apr. 26, 2022
  • Patent Title: Uses Apr. 05, 2022
  • Patent Title: Methods and compositions for sleep disorders and other disorders Dec. 07, 2021
  • Patent Title: 4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms Nov. 23, 2021
  • Patent Title: Combinations of pde1 inhibitors and nep inhibitors Nov. 09, 2021
  • Patent Title: Compositions and methods Sep. 21, 2021
  • Patent Title: Organic compounds Aug. 24, 2021
  • Patent Title: Preparation of certain substituted 1h-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof Jul. 20, 2021
  • Patent Title: Methods Jul. 06, 2021
  • Patent Title: Transmucosal methods for treating psychiatric and neurological conditions Jul. 06, 2021
  • Patent Title: Pharmaceutical capsule compositions comprising lumateperone mono-tosylate Jul. 06, 2021
  • Patent Title: Methods of treating bipolar disorder Jun. 08, 2021
  • Patent Title: Co-crystals of 1-(4-fluoro-phenyl)-4-((6br,1oas)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h,7h- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide May. 25, 2021
  • Patent Title: Pharmaceutical compositions for sustained or delayed release Mar. 30, 2021
  • Patent Title: Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders Mar. 30, 2021
  • Patent Title: Methods of treating schizophrenia and depression Mar. 30, 2021
  • Patent Title: Organic compounds Feb. 02, 2021
  • Patent Title: Organic compounds Jan. 26, 2021
  • Patent Title: Pharmaceutical compositions comprising 4-(6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h, 7h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one and methods of treating conditions of the central nervous system Nov. 24, 2020
  • Patent Title: Organic compounds Oct. 13, 2020
  • Patent Title: Transmucosal and subcutaneous compositions Jul. 21, 2020
  • Patent Title: Methods and compositions for sleep disorders and other disorders Jul. 07, 2020
  • Patent Title: Pharmaceutical capsule compositions comprising lumateperone mono-tosylate Jun. 30, 2020
  • Patent Title: Organic compounds Jun. 23, 2020
  • Patent Title: Uses Jun. 16, 2020
  • Patent Title: Compositions and methods Jun. 16, 2020
  • Patent Title: Salts and crystals of iti-007 May. 19, 2020
  • Patent Title: Organic compounds Feb. 18, 2020
  • Patent Title: Organic compounds Jan. 28, 2020
  • Patent Title: Pharmaceutical compositions comprising 4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h,7h-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl) butan-1-one for inhibiting serotonin reuptake transporter activity Nov. 12, 2019
  • Patent Title: Pharmaceutical compositions comprising ((6br,10as)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl)butan-1-one or pharmaceutically acceptable salts thereof Nov. 05, 2019
  • Patent Title: Uses Sep. 03, 2019
  • Patent Title: Methods Jun. 18, 2019
  • Patent Title: Organic compounds May. 28, 2019
  • Patent Title: Combinations of pde1 inhibitors and nep inhibitors and associated methods May. 14, 2019
  • Patent Title: Organic compounds Apr. 02, 2019
  • Patent Title: Organic compounds Mar. 26, 2019
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of ITCI in WallStreetBets Daily Discussion

ITCI News

Recent insights relating to ITCI

CNBC Recommendations

Recent picks made for ITCI stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ITCI

Corporate Flights

Flights by private jets registered to ITCI